BioAffinity Case Study Shows CyPath Lung Avoids Costly Biopsy; Stock Up

bioAffinity released a case study showing its noninvasive CyPath Lung test provided actionable results that enabled a high‑risk patient to avoid an invasive lung biopsy. The case supports CyPath Lung's clinical utility and could aid commercialization and reduce biopsy‑related risk, but the evidence is limited to a single patient and broader validation is required.

Analysis

bioAffinity released a case study showing its noninvasive CyPath Lung test provided actionable results that enabled a high‑risk patient to avoid an invasive lung biopsy. The case supports CyPath Lung's clinical utility and could aid commercialization and reduce biopsy‑related risk, but the evidence is limited to a single patient and broader validation is required.